In vivo assembly of nanoparticle components to improve targeted cancer imaging

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 25, 2010, Pages 11194-11199

  Perrault, Steven D ^a   Chan, Warren C W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GNP A568; GNP A750; STREPTAVIDIN; UNCLASSIFIED DRUG; FLUORESCENT DYE; MACROGOL DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG DISCRIMINATION; FLUORESCENCE ANALYSIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL NOISE RATIO; TUMOR LOCALIZATION; ANIMAL; BIOTINYLATION; CALIBRATION; CHEMISTRY; DIAGNOSTIC IMAGING; DIFFUSION; FLUORESCENCE MICROSCOPY; HUMAN; KINETICS; METHODOLOGY; NANOTECHNOLOGY; NEOPLASM; PATHOLOGY;

ANIMALS; BIOTINYLATION; CALIBRATION; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DIFFUSION; FLUORESCENT DYES; HUMANS; KINETICS; MICE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 77954920912     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001367107     Document Type: Article

References (31)

1. Weissleder R, Pittet MJ (2008) Imaging in the era of molecular oncology. Nature 452:580-589.
2. Schmidt GP, Reiser MF, Baur-Melnyk A (2009) Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 70:393-400.
3. Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782.
4. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9:1909-1915.
5. Larsen EK, et al. (2009) Size-dependent accumulation of PEGylated silane-coated magnetic iron oxide nanoparticles in murine tumors. ACS Nano 3:1947-1951.
6. Yuan F, et al. (1995) Vascular-permeability in a human tumor xenograft - molecular-size dependence and cutoff size. Cancer Res 55:3752-3756.
7. Fang C, et al. (2006) In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. Eur J Pharm Sci 27:27-36.
8. Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241-263.
9. Hobbs SK, et al. (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612.
10. Ayyagari AL, et al. (2006) Long-circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson Med 55:1023-1029.
11. Chen W, et al. (2010) RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J.
12. Gao XH, et al. (2005) In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol 16:63-72.
13. Akerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E (2002) Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 99:12617-12621.
14. Park J, et al. (2010) Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. Adv Mater 22:880-885.
15. Park J, et al. (2010) Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci USA 107:981-986.
16. Simberg D, et al. (2007) Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 104:932-936.
17. Decuzzi P, Pasqualini R, Arap W, Ferrari M (2009) Intravascular delivery of particulate systems: Does geometry really matter? Pharm Res 26:235-243.
18. Tam F, Goodrich GP, Johnson BR, Halas NJ (2007) Plasmonic enhancement of molecular fluorescence. Nano Lett 7:496-501.
19. Cheng D, Xu Q (2007) Separation distance dependent fluorescence enhancement of fluorescein isothiocyanate by silver nanoparticles. Chem Commun 248-250.
20. Chou LYT, Fischer HC, Perrault SD, Chan WCW (2009) Visualizing quantum dots in biological samples using silver staining. Anal Chem 81:4560-4565.
21. Pimm MV, Fells HF, Perkins AC, Baldwin RW (1988) I-131 and in-111 labeled avidin and streptavidin for pre-targeted immunoscintigraphy with biotinylated anti-tumor monoclonal-antibody. Nucl Med Commun 9:931-941.
22. VanosdolWW, Sung C, Dedrick RL,Weinstein JN (1993) A distributed pharmacokinetic model of 2-step imaging and treatment protocols - application to streptavidin-conjugated monoclonal-antibodies and radiolabeled biotin. J Nucl Med 34:1552-1564.
23. Saga T, et al. (1994) 2-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res 54:2160-2165.
24. AlvarezDiez TM, Polihronis J, Reilly RM (1996) Pretargeted tumor imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and in-111-DTPA-biocytin. Nucl Med Biol 23:459-466.
25. Paganelli G, et al. (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348-357.
26. Sakahara H, Saga T (1999) Avidin-biotin system for delivery of diagnostic agents. Adv Drug Deliver Rev 37:89-101.
27. Ntziachristos V, Ripoll J, Wang LHV,Weissleder R (2005) Looking and listening to light: The evolution of whole-body photonic imaging. Nat Biotechnol 23:313-320.
28. Gao XH, Cui YY, Levenson RM, Chung LWK, Nie SM(2004) In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22:969-976.
29. Choi HS, et al. (2009) Design considerations for tumor-targeted nanoparticles. Nat Nanotechnol 5:42-47.
30. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188:759-768.
31. Frens G (1973) Controlled nucleation for regulation of particle-size in monodisperse gold suspensions. Nat Phys Sci 241:20-22.